Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsMatt Abernethy is recorded as CFO at Neurocrine Biosciences Inc (NBIX). Matt Abernethy has spoken on 20 earnings calls and 3 other investor events across 1 company, most recently for Neurocrine Biosciences Inc on September 9, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“Well, happy to be here and happy to be called an exciting company. I think that we are an exciting company, and we were talking beforehand. We're treated a little bit like a value company at the moment, but we are a growth company.”
“For the second quarter, we delivered over $950 million of total revenue, representing nearly 40% year-over-year growth. This reflects full-quarter contributions from Ingressa and Crenicity, along with a partial quarter contribution from Vicat XR following the close of the Soleno acquisition.”
“So, you know, know, I think the team that we've inherited are very motivated to help these patients.”
“Miles did disclose that he just came from Scotland is that right? I did I did.”
“First, congratulations to our commercial and medical teams on an outstanding quarter. We delivered more than $800 million in total revenue with over 40% year-over-year growth.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
